flow trial semaglutide kidney outcomes In FLOW, semaglutide, a GLP-1 RA, reduced the risk of major outcomes, MACE and all-cause mortality in people with T2D and CKD, regardless of baseline mineralocorticoid receptor antagonist use. @ADA_Pubs Read The FLOW trial for semaglutide

Rationale: Tesamorelin is FDA-approved for reducing visceral fat Ipamorelin adds complementary GH stimulation Combined effect on body composition Note: Tesamorelin is more expensive and prescription-only in many contexts

Benefits of L-Arginine: Knowing the Good Guys from the Bad Research has shown that in intravenous or supplement form, L-arginine supports the production of one of the good guysendothelium-derived nitric oxide (EDNO)

Exenatide treatment ameliorates these morphological alterations and inhibits the mitochondrial apoptotic pathway by suppressing cytochrome c release and favorably modulating the expression of pro-apoptotic (Bax, caspase-3) and anti-apoptotic (Bcl-2) proteins, thereby protecting RGC-5 cells from hyperglycemic injury [43]

[DOI] [PMC free article] [PubMed] [Google Scholar] 445.Xie Y, et al

15.4% of you in Madera County smoke

Want to understand the genetic pathways behind your own biology